Enable JavaScript to visit this website.

Endocrine Global Eligibility Page

Academic Eligibility

To be eligible for a young investigator award, applicants must

  • have a professional degree (MD, PhD, PharmD or equivalent)
  • be no more than 10 years post-graduate training

Investigators must be early in their career (or early stage), preferably within 10 years of completing his/her post-graduate degree, or within 10 years of completing medical residency (or the equivalent).

Investigators must be qualified to carry out the proposed investigation. Assessments of investigator qualification will be made on the basis of their commitment to research in this area, a dedicated faculty assignment for at least one year and previous research and publication experience.


Research Requirements

Investigators are expected to generate exploratory data to better understand disease pathogenesis, genetic risk factors, potential new therapeutic targets or clinical responses, including adherence to therapy.

Criteria for Selection

The ASPIRE review committee will be comprised of a Pfizer independent panel of medical and scientific experts in endocrinology.

In their evaluation, the Committee members consider:

  • Scientific merit of the research proposal
  • Qualifications of the Applicant
  • Relevance of proposed research to the program's mission
  • Evidence of the applicant's commitment to an academic research career
  • Evidence of a suitable research environment
  • Evidence of suitable mentors

Other Funding

No other government, non-governmental, or industry-sponsored funding may cover the same work scope as the grant application to the ASPIRE Program. However, an ASPIRE Program grant may be related to other funding from foundations or government agencies, as long as there is no direct overlap. It is the responsibility of the Applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding.

Once awarded, an ASPIRE grant cannot be amended upwards with additional funding support from Pfizer (via the standard IIR process or separate competitive grant program), nor can additional drug support above and beyond what is sufficient to complete the original study as reviewed and approved by the Review Committee be provided. If supplemental funding is required, it must be secured from sources outside of Pfizer. Similarly, an ongoing Pfizer supported standard IIR cannot apply for supplemental funding via a Pfizer supported competitive grants program. ASPIRE Program grants cannot be provided to studies that are already in progress.


[email protected]